Prediction of combination effect of quinidine on the pharmacokinetics of tipepidine using a physiologically based pharmacokinetic model

References

• Abdel-Rahman SM, Marcucci K, Boge T, Gotschall RR, Kearns GL, Leeder JS. 1999. Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine. Drug Metab Dispos. 27(7):770–775.
   PubMed Web of Science ®Google Scholar
• Balwani M, Burrow TA, Charrow J, Goker-Alpan O, Kaplan P, Kishnani PS, Mistry P, Ruskin J, Weinreb N. 2016. Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States. Mol Genet Metab. 117(2):95–103. doi: 10.1016/j.ymgme.2015.09.002.
   PubMed Web of Science ®Google Scholar
• Chiba K, Kato M, Ito T, Suwa T, Sugiyama Y. 2012. Inter-individual variability of in vivo CYP2D6 activity in different genotypes. Drug Metab Pharmacokinet. 27(4):405–413. doi: 10.2133/dmpk.dmpk-11-rg-078.
   PubMed Web of Science ®Google Scholar
• Dehbozorghi S, Bagheri S, Moradi K, Shokraee K, Mohammadi MR, Akhondzadeh S. 2019. Efficacy and safety of tipepidine as adjunctive therapy in children with attention-deficit/hyperactivity disorder: randomized, double-blind, placebo-controlled clinical trial. Psychiatry Clin Neurosci. 73(11):690–696. doi: 10.1111/pcn.12913.
   PubMed Web of Science ®Google Scholar
• Ebisawa A, Hiratsuka M, Sakuyama K, Konno Y, Sasaki T, Mizugaki M. 2005. Two novel single nucleotide polymorphisms (SNPs) of the CYP2D6 gene in Japanese individuals. Drug Metab Pharmacokinet. 20(4):294–299. doi: 10.2133/dmpk.20.294.
   PubMedGoogle Scholar
• Frederiksen T, Areberg J, Schmidt E, Bjerregaard Stage T, Brøsen K. 2021. Quantification of in vivo metabolic activity of CYP2D6 genotypes and alleles through population pharmacokinetic analysis of vortioxetine. Clin Pharmacol Ther. 109(1):150–159. doi: 10.1002/cpt.1972.
   PubMed Web of Science ®Google Scholar
• Hayashi S, Kawaguchi H, Watanabe T, Miyawaki I, Fukami T, Nakajima M. 2023. Estimation of contribution of CYP2D6 to tipepidine metabolism in humans and prolongation of the half-life of tipepidine by combination use with a CYP2D6 inhibitor in chimeric mice with humanised liver. Xenobiotica. 53(4):241–247. doi: 10.1080/00498254.2023.2224863.
   PubMed Web of Science ®Google Scholar
• Honda S, Kawaura K, Soeda F, Shirasaki T, Takahama K. 2011. The potent inhibitory effect of tipepidine on marble-burying behavior in mice. Behav Brain Res. 216(1):308–312. doi: 10.1016/j.bbr.2010.08.010.
   PubMed Web of Science ®Google Scholar
• Hoobehfekr S, Moghaddam HS, Shalbafan M, Hashemi MG, Pirmoradi MM, Sakenian A, Poopak A, Kashefinejad S, Yarahmadi M, Akhondzadeh S. 2021. Efficacy and safety of tipepidine as adjunctive therapy in major depressive disorder: a randomized, double-blind, placebo-controlled clinical trial. Psychiatry Clin Neurosci. 75(2):57–62. doi: 10.1111/pcn.13180.
   PubMed Web of Science ®Google Scholar
• Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones H, Kakar SM, Nakai Y, Smith BJ, Webster R, et al. 2009. Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol. 49(5):513–533. doi: 10.1177/0091270009333209.
   PubMed Web of Science ®Google Scholar
• Imai Y, Ishii W, Endo A, Arakawa C, Kohira R, Fujita Y, Fuchigami T, Mugishima H. 2011. Tipepidine hibenzate intoxication. Pediatr Int. 53(5):779–781. doi: 10.1111/j.1442-200X.2010.03297.x.
   PubMed Web of Science ®Google Scholar
• Kawaura K, Ogata Y, Inoue M, Honda S, Soeda F, Shirasaki T, Takahama K. 2009. The centrally acting non-narcotic antitussive tipepidine produces antidepressant-like effect in the forced swimming test in rats. Behav Brain Res. 205(1):315–318. doi: 10.1016/j.bbr.2009.07.004.
   PubMed Web of Science ®Google Scholar
• Lobell M, Sivarajah V. 2003. In silico prediction of aqueous solubility, human plasma protein binding and volume of distribution of compounds from calculated pKa and AlogP98 values. Mol Divers. 7(1):69–87. doi: 10.1023/b:modi.0000006562.93049.36.
   PubMed Web of Science ®Google Scholar
• Lu C, Berg C, Prakash SR, Lee FW, Balani SK. 2008. Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. III. In vitro-in vivo correlation with fluconazole. Drug Metab Dispos. 36(7):1261–1266. doi: 10.1124/dmd.107.019000.
   PubMed Web of Science ®Google Scholar
• Maldonado R. 2013. Comparison of the pharmacokinetics and clinical efficacy of new extended-release formulations of methylphenidate. Expert Opin Drug Metab Toxicol. 9(8):1001–1014. doi: 10.1517/17425255.2013.786041.
   PubMed Web of Science ®Google Scholar
• Mao J, Mohutsky MA, Harrelson JP, Wrighton SA, Hall SD. 2012. Predictions of cytochrome P450-mediated drug-drug interactions using cryopreserved human hepatocytes: comparison of plasma and protein-free media incubation conditions. Drug Metab Dispos. 40(4):706–716. doi: 10.1124/dmd.111.043158.
   PubMed Web of Science ®Google Scholar
• Miki R, Honda I, Hamasaki R, Kawahara R, Soeda F, Shirasaki T, Misumi S, Takahama K. 2019. Effects of tipepidine on MK-801-induced cognitive impairment in mice. Brain Res. 1710:230–236. doi: 10.1016/j.brainres.2018.12.032.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Toshimoto K, Lee W, Imamura CK, Tanigawara Y, Sugiyama Y. 2018. Application of PBPK modeling and virtual clinical study approaches to predict the outcomes of CYP2D6 genotype-guided dosing of tamoxifen. CPT Pharmacometrics Syst Pharmacol. 7(7):474–482. doi: 10.1002/psp4.12307.
   PubMedGoogle Scholar
• PMDA 2023. Asverin interview form https://www.info.pmda.go.jp/go/interview/2/430920_2249003B1037_2_010_1F.pdf.
   Google Scholar
• Pope LE, Khalil MH, Berg JE, Stiles M, Yakatan GJ, Sellers EM. 2004. Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers. J Clin Pharmacol. 44(10):1132–1142. doi: 10.1177/0091270004269521.
   PubMed Web of Science ®Google Scholar
• Saito T, Yamashita Y, Tomoda A, Okada T, Umeuchi H, Iwamori S, Shinoda S, Mizuno-Yasuhira A, Urano H, Nishino I, et al. 2020. Using the drug repositioning approach to develop a novel therapy, tipepidine hibenzate sustained-release tablet (TS-141), for children and adolescents with attention-deficit/hyperactivity disorder. BMC Psychiatry. 20(1):530. doi: 10.1186/s12888-020-02932-2.
   PubMed Web of Science ®Google Scholar
• Sasaki T, Hashimoto K, Tachibana M, Kurata T, Okawada K, Ishikawa M, Kimura H, Komatsu H, Ishikawa M, Hasegawa T, et al. 2014a. Tipepidine in children with attention deficit/hyperactivity disorder: a 4-week, open-label, preliminary study. Neuropsychiatr Dis Treat. 10:147–151. doi: 10.2147/NDT.S58480.
   PubMed Web of Science ®Google Scholar
• Sasaki T, Hashimoto K, Tachibana M, Kurata T, Kimura H, Komatsu H, Ishikawa M, Hasegawa T, Shiina A, Hashimoto T, et al. 2014b. Tipepidine in adolescent patients with depression: a 4 week, open-label, preliminary study. Neuropsychiatr Dis Treat. 10:719–722. doi: 10.2147/NDT.S63075.
   PubMed Web of Science ®Google Scholar
• Soeda F, Fujieda Y, Kinoshita M, Shirasaki T, Takahama K. 2016. Centrally acting non-narcotic antitussives prevent hyperactivity in mice: involvement of GIRK channels. Pharmacol Biochem Behav. 144:26–32. doi: 10.1016/j.pbb.2016.02.006.
   PubMed Web of Science ®Google Scholar
• Sychterz C, Gardner I, Chiang M, Rachumallu R, Neuhoff S, Perera V, Merali S, Schmidt BJ, Gaohua L. 2022. Performance verification of CYP2C19 enzyme abundance polymorphism settings within the Simcyp Simulator v21. Metabolites. 12(10):1001. doi: 10.3390/metabo12101001.
   PubMed Web of Science ®Google Scholar
• Uchaipichat V, Winner LK, Mackenzie PI, Elliot DJ, Williams JA, Miners JO. 2006. Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. Br J Clin Pharmacol. 61(4):427–439. doi: 10.1111/j.1365-2125.2006.02588.x.
   PubMed Web of Science ®Google Scholar
• VandenBrink BM, Foti RS, Rock DA, Wienkers LC, Wahlstrom JL. 2012. Prediction of CYP2D6 drug interactions from in vitro data: evidence for substrate-dependent inhibition. Drug Metab Dispos. 40(1):47–53. doi: 10.1124/dmd.111.041210.
   PubMed Web of Science ®Google Scholar
• Yoon DY, Lee S, Jang IJ, Kim M, Lee H, Kim S, Kim B, Song GS, Rhee SJ. 2021. Prediction of drug-drug interaction potential of tegoprazan using physiologically based pharmacokinetic modeling and simulation. Pharmaceutics. 13(9):1489. doi: 10.3390/pharmaceutics13091489.
   PubMed Web of Science ®Google Scholar